Personal information

No personal information available

Activities

Employment (2)

Merck: North Wales, Pennsylvania, US

2023-07-17 to present
Employment
Source: Self-asserted source
Nancy Davis

Vanderbilt University Medical Center: Nashville, TN, US

2018-02-26 to 2023-07-31 | Associate Professor of Medicine & Urology (Medicine, Division of Hematology & Oncology)
Employment
Source: Self-asserted source
Nancy Davis

Professional activities (3)

European Society for Medical Oncology: Lugano, CH

Membership
Source: Self-asserted source
Nancy Davis

American Urological Association: Linthicum, MD, US

Membership
Source: Self-asserted source
Nancy Davis

American Society of Clinical Oncology: Alexandria, Virginia, US

Membership
Source: Self-asserted source
Nancy Davis

Works (26)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

Journal of Clinical Oncology
2023-02-01 | Journal article
Contributors: Joseph W. Kim; Rana R. McKay; Marc R. Radke; Shilin Zhao; Mary-Ellen Taplin; Nancy B. Davis; Paul Monk; Leonard J. Appleman; Primo N. Lara, Jr; Ulka N. Vaishampayan et al.
Source: check_circle
Crossref

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.

JAMA oncology
2022-09-01 | Journal article | Writing - review & editing, Investigation
Contributors: Nancy Davis
Source: Self-asserted source
Nancy Davis

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Cancers
2022-08-07 | Journal article
Contributors: Yu-Wei Chen; Matthew D. Tucker; Landon C. Brown; Hesham A. Yasin; Kristin K. Ancell; Andrew J. Armstrong; Kathryn E. Beckermann; Nancy B. Davis; Michael R. Harrison; Elizabeth G. Kaiser et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer
2022-03-15 | Journal article
Part of ISSN: 0008-543X
Part of ISSN: 1097-0142
Source: Self-asserted source
Nancy Davis

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Biomarker Research
2021-12 | Journal article
Part of ISSN: 2050-7771
Source: Self-asserted source
Nancy Davis

Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.

Cancer
2021-06-23 | Journal article
Source: Self-asserted source
Nancy Davis

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma

Cancers
2021-03-23 | Journal article
Part of ISSN: 2072-6694
Source: Self-asserted source
Nancy Davis

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.

Frontiers in oncology
2020-12-22 | Journal article
Source: Self-asserted source
Nancy Davis

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.

JCI insight
2020-11-19 | Journal article
Source: Self-asserted source
Nancy Davis

Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience.

Clinical genitourinary cancer
2020-07-16 | Journal article
Source: Self-asserted source
Nancy Davis

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-04-09 | Journal article
Source: Self-asserted source
Nancy Davis

Systemic Therapy for Melanoma: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-03-31 | Journal article
Source: Self-asserted source
Nancy Davis

Editorial Comment.

The Journal of urology
2020-03-17 | Journal article
Source: Self-asserted source
Nancy Davis

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

The Lancet. Oncology
2019-08-16 | Journal article
Source: Self-asserted source
Nancy Davis
grade
Preferred source (of 2)‎

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2017-02-27 | Journal article
Source: Self-asserted source
Nancy Davis

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)
2011-11-28 | Journal article
Source: Self-asserted source
Nancy Davis

Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series.

Journal of palliative medicine
2010-09-01 | Journal article
Source: Self-asserted source
Nancy Davis
grade
Preferred source (of 2)‎

Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.

Leukemia research
2008-03-04 | Journal article
Source: Self-asserted source
Nancy Davis

A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.

Clinical genitourinary cancer
2008-03-01 | Journal article
Source: Self-asserted source
Nancy Davis

Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data.

BMC urology
2007-02-05 | Journal article
Source: Self-asserted source
Nancy Davis

Carcinoid tumors.

American family physician
2006-08-01 | Journal article
Source: Self-asserted source
Nancy Davis

Intra-abdominal desmoid tumor following retroperitoneal lymph node dissection for testicular germ cell tumor.

International journal of urology : official journal of the Japanese Urological Association
2006-01-01 | Journal article
Source: Self-asserted source
Nancy Davis

A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.

BJU international
2005-10-01 | Journal article
Source: Self-asserted source
Nancy Davis

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2004-01-01 | Journal article
Source: Self-asserted source
Nancy Davis

Selecting a secondary treatment.

The Urologic clinics of North America
2003-05-01 | Journal article
Source: Self-asserted source
Nancy Davis

Does PC-SPEs interact with warfarin?

The Journal of urology
2002-04-01 | Journal article
Source: Self-asserted source
Nancy Davis